Health Canada has approved Koselugo (selumetinib) for adults living with NF1 who have symptomatic and inoperable plexiform neurofibromas. This marks an important milestone for individuals who have long had very limited treatment options.

The approval was based on positive results from KOMET, the largest and only placebo-controlled global Phase III trial in this patient population.

This moment also reflects the power of our community.

Many individuals and families shared their experiences through our community survey and contributed to our submission supporting access to this therapy. Your stories helped highlight the urgent need for better treatment options for people living with NF. Progress like this happens when a community speaks up together.

You can read the full press release.